Literature DB >> 15212715

Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.

Karine Breckpot1, Jurgen Corthals, Carlo Heirman, Aude Bonehill, Annelies Michiels, Sandra Tuyaerts, Catherine De Greef, Kris Thielemans.   

Abstract

In this study, we compared dendritic cells (DCs) differentiated from positively selected monocytes (CD14-DCs) to DCs differentiated from adherence-selected monocytes (adh-DCs) with emphasis on lentiviral transduction. Using a second-generation, triple-helix containing, self-inactivating lentiviral vector at a multiplicity of infection (MOI) of 15, we observed enhanced transduction of CD14-DCs (72.8 +/- 5.3%, mean fluorescence intensity [MFI] = 166 +/- 76) compared to adh-DCs (32.3 +/- 13.1%, MFI = 119 +/- 76, n = 5). More importantly, the efficiency to transduce adh-DCs was significantly increased when monocytes were incubated with antiCD14 antibody coupled beads, anti-CD14 antibodies, or lipopolysaccharide (LPS), reaching transduction efficiencies up to 86.6%, 53.3%, and 80.9%, respectively. We showed that this enhanced transduction was correlated to an activation of the monocytes, characterized by the up regulation of the cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha and the de novo synthesis of IL-6 and IL-10. However, the enhanced transduction of immature CD14-DCs was not correlated with a progression in the cell cycle from G(0) to G(1). We further showed that CD14-DCs were phenotypically comparable to adh-DCs. Functional analysis revealed that there were no differences in allostimulatory capacity, production of IL-12 p70 on CD40 ligation or expression of IL-1beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha as evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR). Finally, we showed that lentivirally transduced CD14-DCs were equally capable as adh-DCs in stimulating MAGE-A3 antigen-specific CD4(+) and CD8(+) T cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212715     DOI: 10.1089/104303404323142015

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

Review 1.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

2.  Glycodelin-A stimulates interleukin-6 secretion by human monocytes and macrophages through L-selectin and the extracellular signal-regulated kinase pathway.

Authors:  Cheuk-Lun Lee; Eve Y F Lam; Kevin K W Lam; Hannu Koistinen; Markku Seppälä; Ernest H Y Ng; William S B Yeung; Philip C N Chiu
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

3.  Proteomic biosignatures for monocyte-macrophage differentiation.

Authors:  Stephanie D Kraft-Terry; Howard E Gendelman
Journal:  Cell Immunol       Date:  2011-07-08       Impact factor: 4.868

4.  Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy.

Authors:  Timo Buhl; Tobias J Legler; Albert Rosenberger; Anke Schardt; Michael P Schön; Holger A Haenssle
Journal:  Cancer Immunol Immunother       Date:  2012-04-22       Impact factor: 6.968

5.  Vpx-Independent Lentiviral Transduction and shRNA-Mediated Protein Knock-Down in Monocyte-Derived Dendritic Cells.

Authors:  Wojciech Witkowski; Jolien Vermeire; Alessia Landi; Evelien Naessens; Hanne Vanderstraeten; Hans Nauwynck; Herman Favoreel; Bruno Verhasselt
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Targeting lentiviral vectors for cancer immunotherapy.

Authors:  Frederick Arce; Karine Breckpot; Mary Collins; David Escors
Journal:  Curr Cancer Ther Rev       Date:  2011-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.